Literature DB >> 18595765

Mild cognitive impairment is common in Parkinson's disease patients with normal Mini-Mental State Examination (MMSE) scores.

Eugenia Mamikonyan1, Paul J Moberg, Andrew Siderowf, John E Duda, Tom Ten Have, Howard I Hurtig, Matthew B Stern, Daniel Weintraub.   

Abstract

PURPOSE: Cognitive impairment occurs in the majority of Parkinson's disease (PD) patients, but little is known about detection of mild cognitive impairment (MCI) in this population. We report on the frequency and characteristics of cognitive deficits in PD patients with intact global cognition based on Mini-Mental State Examination (MMSE) performance.
METHODS: One hundred and six PD patients with normal age- and education-adjusted MMSE scores (mean [SD] score=29.1 [1.1]) were administered standardized neuropsychological tests assessing memory, executive function, and attention. Impairment on a cognitive domain was a low score (i.e., >or=1.5 SD below the published normative mean) on at least two measures or tests (for memory and executive abilities) or a single measure (for attention).
RESULTS: Mild cognitive impairment was found in 29.2% of PD patients, with 17.9% demonstrating single domain and 11.3% multiple domain impairment. Memory and attention impairment were most common (15.1% and 17.0%, respectively), followed by executive impairment (8.5%). Depending on the measure of disease severity chosen, increasing age and disease severity, anti-anxiety medication use, and a suggestion for increasing severity of daytime sleepiness were independent predictors of cognitive impairment.
CONCLUSIONS: Cognitive deficits are common in PD patients with "normal" cognition based on MMSE performance, suggesting that MCI is under-recognized in clinical practice due to routine use of insensitive screening instruments. In contrast with some previous reports, early memory impairment may be as common as either executive or attentional deficits in PD. In addition, psychiatric medication use and daytime sleepiness may be reversible or treatable contributors to cognitive impairment.

Entities:  

Mesh:

Year:  2008        PMID: 18595765      PMCID: PMC2668811          DOI: 10.1016/j.parkreldis.2008.05.006

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  33 in total

1.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician.

Authors:  M F Folstein; S E Folstein; P R McHugh
Journal:  J Psychiatr Res       Date:  1975-11       Impact factor: 4.791

2.  Staging of brain pathology related to sporadic Parkinson's disease.

Authors:  Heiko Braak; Kelly Del Tredici; Udo Rüb; Rob A I de Vos; Ernst N H Jansen Steur; Eva Braak
Journal:  Neurobiol Aging       Date:  2003 Mar-Apr       Impact factor: 4.673

3.  Fluctuations in attention: PD dementia vs DLB with parkinsonism.

Authors:  C G Ballard; D Aarsland; I McKeith; J O'Brien; A Gray; F Cormack; D Burn; T Cassidy; R Starfeldt; J-P Larsen; R Brown; M Tovee
Journal:  Neurology       Date:  2002-12-10       Impact factor: 9.910

4.  The meaning of cognitive impairment in the elderly.

Authors:  M Folstein; J C Anthony; I Parhad; B Duffy; E M Gruenberg
Journal:  J Am Geriatr Soc       Date:  1985-04       Impact factor: 5.562

5.  Development of the University of Pennsylvania Smell Identification Test: a standardized microencapsulated test of olfactory function.

Authors:  R L Doty; P Shaman; M Dann
Journal:  Physiol Behav       Date:  1984-03

6.  The Inventory for Depressive Symptomatology (IDS): preliminary findings.

Authors:  A J Rush; D E Giles; M A Schlesser; C L Fulton; J Weissenburger; C Burns
Journal:  Psychiatry Res       Date:  1986-05       Impact factor: 3.222

7.  Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study.

Authors:  Nicolaas I Bohnen; Daniel I Kaufer; Larry S Ivanco; Brian Lopresti; Robert A Koeppe; James G Davis; Chester A Mathis; Robert Y Moore; Steven T DeKosky
Journal:  Arch Neurol       Date:  2003-12

8.  Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study.

Authors:  Dag Aarsland; Kjeld Andersen; Jan P Larsen; Anette Lolk; Per Kragh-Sørensen
Journal:  Arch Neurol       Date:  2003-03

9.  A longitudinal study of neuropsychological change in individuals with Parkinson's disease.

Authors:  Tamiko Azuma; Robyn F Cruz; Kathryn A Bayles; Cheryl K Tomoeda; Erwin B Montgomery
Journal:  Int J Geriatr Psychiatry       Date:  2003-11       Impact factor: 3.485

10.  The cognitive ability of an incident cohort of Parkinson's patients in the UK. The CamPaIGN study.

Authors:  Thomas Foltynie; Carol E G Brayne; Trevor W Robbins; Roger A Barker
Journal:  Brain       Date:  2003-12-22       Impact factor: 13.501

View more
  60 in total

Review 1.  Mild cognitive impairment in Parkinson's disease.

Authors:  J G Goldman; I Litvan
Journal:  Minerva Med       Date:  2011-12       Impact factor: 4.806

Review 2.  Parkinson's disease dementia and potential therapeutic strategies.

Authors:  John N Caviness; LihFen Lue; Charles H Adler; Douglas G Walker
Journal:  CNS Neurosci Ther       Date:  2010-12-28       Impact factor: 5.243

3.  Clinical differences among mild cognitive impairment subtypes in Parkinson's disease.

Authors:  Jennifer G Goldman; Holly Weis; Glenn Stebbins; Bryan Bernard; Christopher G Goetz
Journal:  Mov Disord       Date:  2012-07-06       Impact factor: 10.338

Review 4.  The Therapeutic Potential of Exercise to Improve Mood, Cognition, and Sleep in Parkinson's Disease.

Authors:  Gretchen O Reynolds; Michael W Otto; Terry D Ellis; Alice Cronin-Golomb
Journal:  Mov Disord       Date:  2015-12-30       Impact factor: 10.338

5.  Behavioral toxicology of cognition: extrapolation from experimental animal models to humans: behavioral toxicology symposium overview.

Authors:  Merle G Paule; Leonard Green; Joel Myerson; Maria Alvarado; Jocelyne Bachevalier; Jay S Schneider; Susan L Schantz
Journal:  Neurotoxicol Teratol       Date:  2012-01-28       Impact factor: 3.763

6.  Defining optimal cutoff scores for cognitive impairment using Movement Disorder Society Task Force criteria for mild cognitive impairment in Parkinson's disease.

Authors:  Jennifer G Goldman; Samantha Holden; Bryan Bernard; Bichun Ouyang; Christopher G Goetz; Glenn T Stebbins
Journal:  Mov Disord       Date:  2013-10-09       Impact factor: 10.338

Review 7.  Mild cognitive impairment exists in Parkinson's disease.

Authors:  Irena Rektorova
Journal:  J Neural Transm (Vienna)       Date:  2011-06-19       Impact factor: 3.575

Review 8.  MDS Task Force on mild cognitive impairment in Parkinson's disease: critical review of PD-MCI.

Authors:  Irene Litvan; Dag Aarsland; Charles H Adler; Jennifer G Goldman; Jaime Kulisevsky; Brit Mollenhauer; Maria C Rodriguez-Oroz; Alexander I Tröster; Daniel Weintraub
Journal:  Mov Disord       Date:  2011-06-09       Impact factor: 10.338

9.  Seniors with Parkinson's disease: initial medical treatment.

Authors:  J Eric Ahlskog
Journal:  J Clin Neurol       Date:  2010-12-31       Impact factor: 3.077

10.  Validity and metric of MiniMental Parkinson and MiniMental State Examination in Parkinson's disease.

Authors:  V Isella; C Mapelli; N Morielli; D De Gaspari; C Siri; G Pezzoli; A Antonini; M Poletti; U Bonuccelli; L Picchi; A Napolitano; M Vista; A Greco; I M Appollonio
Journal:  Neurol Sci       Date:  2013-02-20       Impact factor: 3.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.